AI주식인사이트AI Stock Insight
B

온코닉테라퓨틱스

476060KOSDAQ자연과학 및 공학 연구개발업

62.3 / 100

Reference Date: 2026-04-13

Financial Score29.5 / 40
News Sentiment15.8 / 25
Momentum7.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but PBR raises overvaluation concerns. Plunged 19.3% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Onconic Therapeutics focuses on developing innovative drugs for unmet medical needs in gastroesophageal reflux disease and oncology, emphasizing cost-effective small-molecule compounds. Its key product, 'Zastaprazan,' a P-CAB mechanism drug, has completed Phase 3 trials and received approval, while its next-generation oncology candidate 'Nesuparib' is in various clinical trials.

Number of Employees

38people

Average Salary

78.6M KRW

Score Calculation Basis

Detailed Financial Score

PER
58.91Industry Average 120.078.0Point

Half of industry avg (excellent)

PBR
13.18Industry Average 3.820.0Point

3.5x industry avg (risky)

ROE
24.65Industry Average -32.113.5Point

Well below industry avg

Debt Ratio
0.06Industry Average 7.528.0Point

Half of industry avg (excellent)

Trend 2024~202510.0 / 10 points
Revenue Growth Rate
3.0 / 3

Avg ▲259.8% (1-year basis)

Operating Profit Growth Rate
3.0 / 3

Avg ▲363.0% (1-year basis)

ROE Trend
4.0 / 4

Detailed News Sentiment

8 totalPositive 3Neutral 1Negative 0Average Sentiment Score 76.2

Detailed Momentum

52-week position6.0Point

52w upper range (75%)

Current 21,150Won52-week high 26,30052-week low 5,025
1-month return0.0Point

1m -19.27% (strong drop)

Volume trend1.0Point

Volume decreasing

Detailed Disclosure

5 totalPositive 0Neutral 5Negative 0
  • Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-04-10
  • Neutral투자판단관련주요경영사항(임상시험계획변경승인신청) (자큐보정(JP-1366)의 미란성 위식도역류질환 치료 후 유지요법에 대한 제3상 임상시험)2026-03-31
  • Neutral주식매수선택권부여에관한신고2026-03-23
  • Neutral사외이사의선임ㆍ해임또는중도퇴임에관한신고2026-03-23
  • Neutral정기주주총회결과2026-03-23